Novo Nordisk Says ‍Victoza Significantly Reduces Risk of Major Adverse Cardiovascular Events in Leader Tria​; Says ‍Safety Profile of Victoza in Leader Was Generally Consistent With Previous Liraglutide Clinical Studies​